Duncker Streett & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Duncker Streett & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$934K	Sell	2,091 -20	-0.9%	-$9.33K	0.18%	105
2025 Q4	$957K	Sell	2,111 -244	-10%	-$105K	0.17%	103
2025 Q3	$922K	Sell	2,355 -5,377	-70%	-$2.25M	0.16%	102
2025 Q2	$3.44M	Sell	7,732 -15	-0.2%	-$6.91K	0.63%	39
2025 Q1	$3.76M	Buy	7,747 +84	+1%	+$39.1K	0.74%	35
2024 Q4	$3.09M	Buy	7,663 +335	+5%	+$155K	0.57%	49
2024 Q3	$3.41M	Buy	7,328 +903	+14%	+$434K	0.62%	46
2024 Q2	$3.01M	Buy	+6,425	New	+$2.79M	0.58%	52
2020 Q4	–	Sell	-200	Closed	-$54K	–	563
2020 Q3	$54K	Buy	200 +50	+33%	+$13.8K	0.01%	317
2020 Q2	$44K	Buy	+150	New	+$40.7K	0.01%	330
2019 Q2	–	Sell	-300	Closed	-$55K	–	579
2019 Q1	$55K	Buy	+300	New	+$55.4K	0.01%	365

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Duncker Streett & Co's VRTX Position: Q1 2026 in Review

Duncker Streett & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 0.95% in Q1 2026, selling an estimated $9.33K and leaving 2,091 shares worth $934K. The position accounts for 0.18% of the portfolio, ranked #105.

Duncker Streett & Co first reported a position in VRTX in Q1 2019 and has held it in 11 quarters since. The position peaked at $3.76M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Duncker Streett & Co held 2,091 shares of Vertex Pharmaceuticals worth $934K as of Q1 2026.
Duncker Streett & Co sold 20 Vertex Pharmaceuticals shares in Q1 2026, an estimated $9.33K.
Vertex Pharmaceuticals made up 0.18% of Duncker Streett & Co's portfolio in Q1 2026, its #105 holding.
Duncker Streett & Co first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Duncker Streett & Co's Vertex Pharmaceuticals position peaked at $3.76M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Duncker Streett & Co's 13F filing for Q1 2026, filed 29 Apr 2026.